Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis

NCT02581527 is registered in ClinicalTrials.gov with St George's, University of London as lead sponsor.

NCT NCT02581527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis
Lead sponsor
St George's, University of London
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2017
Completion date
July 31, 2022
Enrollment
672 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis